Houchen Lyu1,2,3,4, Sizheng S Zhao1,5, Kazuki Yoshida1,6, Sara K Tedeschi1,2, Chang Xu1, Sagar U Nigwekar7, Benjamin Z Leder2,8, Daniel H Solomon1,2,9. 1. Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts. 2. Harvard Medical School, Boston, Massachusetts. 3. Department of Orthopedics, Chinese People's Liberation Army General Hospital, Beijing, China. 4. China National Clinical Research Center of Musculoskeletal Diseases, Beijing, China. 5. Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom. 6. Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 7. Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 8. Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 9. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
CONTEXT: Teriparatide and denosumab are effective treatments for osteoporosis and typically reserved as second-line options after patients have used bisphosphonates. However, limited head-to-head comparative effectiveness data exist between teriparatide and denosumab. OBJECTIVE: We compared changes in bone mineral density (BMD) between groups treated with teriparatide or denosumab after using bisphosphonates, focusing on the change in BMD while on either drug over 2 years. DESIGN: Observational cohort study using electronic medical records from two academic medical centers in the United States. PARTICIPANTS: The study population included osteoporotic patients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab. OUTCOME MEASURES: Annualized BMD change from baseline at the lumbar spine, total hip, and femoral neck. RESULTS: Patients treated with teriparatide (n = 110) were compared with those treated with denosumab (n = 105); the mean (SD) age was 70 (10) years and median duration (interquartile range) of bisphosphonate use was 7.0 (5.6 to 9.7) years. Compared with denosumab users, teriparatide users had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%) but lower at the total hip by -2.2% (95% CI -2.9 to -1.5%) and the femoral neck by -1.1% (95% CI -2.1 to -0.1%). Those who switched to teriparatide had a transient loss of hip BMD for the first year, with no overall increase in the total hip BMD over 2 years. CONCLUSIONS: Among patients who use long-term bisphosphonates, the decision of switching to teriparatide should be made with caution, especially for patients at high risk of hip fracture.
CONTEXT: Teriparatide and denosumab are effective treatments for osteoporosis and typically reserved as second-line options after patients have used bisphosphonates. However, limited head-to-head comparative effectiveness data exist between teriparatide and denosumab. OBJECTIVE: We compared changes in bone mineral density (BMD) between groups treated with teriparatide or denosumab after using bisphosphonates, focusing on the change in BMD while on either drug over 2 years. DESIGN: Observational cohort study using electronic medical records from two academic medical centers in the United States. PARTICIPANTS: The study population included osteoporoticpatients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab. OUTCOME MEASURES: Annualized BMD change from baseline at the lumbar spine, total hip, and femoral neck. RESULTS:Patients treated with teriparatide (n = 110) were compared with those treated with denosumab (n = 105); the mean (SD) age was 70 (10) years and median duration (interquartile range) of bisphosphonate use was 7.0 (5.6 to 9.7) years. Compared with denosumab users, teriparatide users had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%) but lower at the total hip by -2.2% (95% CI -2.9 to -1.5%) and the femoral neck by -1.1% (95% CI -2.1 to -0.1%). Those who switched to teriparatide had a transient loss of hip BMD for the first year, with no overall increase in the total hipBMD over 2 years. CONCLUSIONS: Among patients who use long-term bisphosphonates, the decision of switching to teriparatide should be made with caution, especially for patients at high risk of hip fracture.
Authors: Kyle K Nishiyama; Adi Cohen; Polly Young; Ji Wang; Joan M Lappe; X Edward Guo; David W Dempster; Robert R Recker; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2014-03-31 Impact factor: 5.958
Authors: Kazuki Yoshida; Sonia Hernández-Díaz; Daniel H Solomon; John W Jackson; Joshua J Gagne; Robert J Glynn; Jessica M Franklin Journal: Epidemiology Date: 2017-05 Impact factor: 4.822
Authors: Houchen Lyu; Bakr Jundi; Chang Xu; Sara K Tedeschi; Kazuki Yoshida; Sizheng Zhao; Sagar U Nigwekar; Benjamin Z Leder; Daniel H Solomon Journal: J Clin Endocrinol Metab Date: 2019-05-01 Impact factor: 5.958
Authors: Pauline M Camacho; Steven M Petak; Neil Binkley; Bart L Clarke; Steven T Harris; Daniel L Hurley; Michael Kleerekoper; E Michael Lewiecki; Paul D Miller; Harmeet S Narula; Rachel Pessah-Pollack; Vin Tangpricha; Sunil J Wimalawansa; Nelson B Watts Journal: Endocr Pract Date: 2016-09-02 Impact factor: 3.443
Authors: Steven Boonen; Fernando Marin; Barbara Obermayer-Pietsch; Maria E Simões; Clare Barker; Emmett V Glass; Peyman Hadji; George Lyritis; Heide Oertel; Thomas Nickelsen; Eugene V McCloskey Journal: J Clin Endocrinol Metab Date: 2007-12-26 Impact factor: 5.958
Authors: Felicia Cosman; Tony M Keaveny; David Kopperdahl; Robert A Wermers; Xiaohai Wan; Kelly D Krohn; John H Krege Journal: J Bone Miner Res Date: 2013-06 Impact factor: 6.741
Authors: Etah S Kurland; Samantha L Heller; Beverly Diamond; Donald J McMahon; Felicia Cosman; John P Bilezikian Journal: Osteoporos Int Date: 2004-06-03 Impact factor: 4.507
Authors: Yebin Jiang; Jenny J Zhao; Bruce H Mitlak; Ouhong Wang; Harry K Genant; Erik F Eriksen Journal: J Bone Miner Res Date: 2003-11 Impact factor: 6.741
Authors: Felicia Cosman; Robert A Wermers; Christopher Recknor; Karen F Mauck; Li Xie; Emmett V Glass; John H Krege Journal: J Clin Endocrinol Metab Date: 2009-07-07 Impact factor: 5.958
Authors: Houchen Lyu; Sizheng S Zhao; Kazuki Yoshida; Sara K Tedeschi; Chang Xu; Sagar U Nigwekar; Benjamin Z Leder; Daniel H Solomon Journal: J Clin Endocrinol Metab Date: 2019-11-01 Impact factor: 5.958
Authors: Mercè Giner; María Angeles Vázquez-Gámez; María José Miranda; Jesús Bocio-Nuñez; Francisco Jesús Olmo-Montes; Miguel Angel Rico; Miguel Angel Colmenero; María-José Montoya-García Journal: J Clin Med Date: 2022-08-14 Impact factor: 4.964